Compare BioNTech SE - ADR (BNTX) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs iShares MBS ETF — how do they compare? BioNTech SE - ADR trades at $89.87 (market cap $22.86B), while iShares MBS ETF trades at $93.84. The key difference: iShares MBS ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | MBB | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | — |
52-Week High | $119.34 | $96.91 |
52-Week Low | $83.89 | $92.46 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
MBB, the iShares MBS ETF, trades at $93.26, down 0.49% on the day. The technical outlook is bearish, with moving averages signaling a downtrend, though oversold oscillators suggest potential for a near-term bounce. Recent news highlights institutional activity, with some firms increasing stakes while others reduced positions. The ETF continues its dividend distributions, with the latest payment scheduled for July 2026.
The outlook for MBB is mixed, balancing a defensive income stream from mortgage-backed securities against interest rate sensitivity. The primary opportunity lies in its monthly dividend yield, appealing for income-focused investors. Key risks include Federal Reserve policy shifts impacting bond valuations and broader economic conditions affecting the housing market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
